Core One Labs Announces Breakthrough in Solving Psilocybin Dosing Problems by Introducing Biosynthetic Psilocybin to i
January 12, 2021, 4:10 AM EST
VANCOUVER, BC / ACCESSWIRE / January 12, 2021 / Core One Labs Inc.
(CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62) (WKN: A2P8K3) (the "Company"
is
pleased to announce its plans to initiate another intellectual property
strategy that will utilize its patented transmucosal thinstrip delivery method
("thinstrip delivery method" in combination with its proprietary biosynthetic
psilocybin, developed by its wholly-owned subsidiary, Vocan Biotechnologies
Inc. ("Vocan".
The Company's existing thinstrip delivery method has been patented for use
with THC and CBD (CannaStrips^TM) and has the potential for use with all
naturally occurring compounds, including psilocybin
Through cutting-edge research by the Company's team at Vocan, a cost effective
method for producing biosynthesized psilocybin has been developed. This low
cost method of psilocybin production, in combination with the incorporation of
psilocybin into the Company's thinstrip technology, will result in an
innovative and first-to-market delivery method of psilocybin for medical
purposes.
Core One's objective in developing the psilocybin thinstrips is to assist with
the delivery of revolutionary psychedelic treatment methods to address mental
health conditions such as depression, anxiety and addictions.
Methods of accurate dosing and effective delivery of psilocybin have gone
relatively under-researched, and current methods utilized by companies using
traditional oral delivery methods can cause hallucinations, digestive issues,
and inaccurate dosages resulting in undesired side effects. The Company's
patented sublingual transmucosal (orally dissolvable) thinstrip technology,
for the delivery of psilocybin, will aim to address these issues, and
anticipates the provision of many potential advantages and benefits such as
the rapid dissolving and onset of action to the bloodstream, as well as
concentration control and time released dosing. Thinstrip delivery technology
is a natural, non-toxic, biodegradable, biocompatible composite, which is user
friendly. The sublingual polymer thinstrip, with nano particulated active
ingredients, skips the digestive system and is absorbed directly into the
bloodstream through the membranes in the mouth, resulting in optimum
bioavailability (absorption percentage) of the active ingredients. Direct
delivery to the bloodstream means that dosages can be less potent with the
same affect.
According to the World Health Organization, almost 350 million people
worldwide were affected by depression in 2016. Common antidepressant drugs
help maintain the balance of various hormones and chemicals in the brain which
assists in the treatment of depression.
The Center for Disease Control and Prevention (CDC), reported that the
percentage of people above the age of 12 years using antidepressants in the
U.S. rose 12.7% in 2011-2014. According to MedGadget, the antidepressant drug
market was valued at $13.69 billion in 2018 and is expected to reach $15.88
billion by 2025. The CDC said that in the U.S., antidepressants were the most
commonly prescribed drugs in 2013 and from over 16 million long term users,
around 70% are female.
"One of the critical issues surrounding the use of psilocybin is accurate
dosing in oral delivery methods. Our breakthrough technology is a game changer
in the psychedelic space and has the potential to revolutionize the way
patients receive psychedelics as medicine and reduce over concentrations and
resulting adverse effects." stated Dr. Robert E.W. Hancock, Executive Chairman
of the Company.
About Core One Labs Inc.
Core One Labs Inc. is a research and technology company focused in life
sciences and on bringing psychedelic medicines to market through novel
delivery systems and psychedelic assisted psychotherapy. The Company has
developed a patent pending thin film oral strip (the "technology" which
dissolves instantly when placed in the mouth and delivers organic molecules in
precise quantities to the bloodstream, maintaining excellent bioavailability.
With this technology, the Company intends to further develop its technology to
focus on delivering psychedelic molecules with an initial focus on psilocybin.
Core One also holds an interest in walk-in medical clinics which maintain a
database of over 200,000 patients combined. Through research and development
in these clinics, including the integration of its intellectual property
related to psychedelic treatments and novel drug therapies, the Company
intends to work towards regulatory approval for research that advances
psychedelic-derived treatments for mental health disorders.
Core One Labs Inc.
Joel Shacker
Chief Executive Officer
FOR MORE INFORMATION, PLEASE CONTACT:
info@core1labs.com
1-866-347-5058
TOODLES
January 12, 2021, 4:10 AM EST
VANCOUVER, BC / ACCESSWIRE / January 12, 2021 / Core One Labs Inc.
(CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62) (WKN: A2P8K3) (the "Company"
is pleased to announce its plans to initiate another intellectual property
strategy that will utilize its patented transmucosal thinstrip delivery method
("thinstrip delivery method"
in combination with its proprietary biosynthetic psilocybin, developed by its wholly-owned subsidiary, Vocan Biotechnologies
Inc. ("Vocan"
. The Company's existing thinstrip delivery method has been patented for use
with THC and CBD (CannaStrips^TM) and has the potential for use with all
naturally occurring compounds, including psilocybin
Through cutting-edge research by the Company's team at Vocan, a cost effective
method for producing biosynthesized psilocybin has been developed. This low
cost method of psilocybin production, in combination with the incorporation of
psilocybin into the Company's thinstrip technology, will result in an
innovative and first-to-market delivery method of psilocybin for medical
purposes.
Core One's objective in developing the psilocybin thinstrips is to assist with
the delivery of revolutionary psychedelic treatment methods to address mental
health conditions such as depression, anxiety and addictions.
Methods of accurate dosing and effective delivery of psilocybin have gone
relatively under-researched, and current methods utilized by companies using
traditional oral delivery methods can cause hallucinations, digestive issues,
and inaccurate dosages resulting in undesired side effects. The Company's
patented sublingual transmucosal (orally dissolvable) thinstrip technology,
for the delivery of psilocybin, will aim to address these issues, and
anticipates the provision of many potential advantages and benefits such as
the rapid dissolving and onset of action to the bloodstream, as well as
concentration control and time released dosing. Thinstrip delivery technology
is a natural, non-toxic, biodegradable, biocompatible composite, which is user
friendly. The sublingual polymer thinstrip, with nano particulated active
ingredients, skips the digestive system and is absorbed directly into the
bloodstream through the membranes in the mouth, resulting in optimum
bioavailability (absorption percentage) of the active ingredients. Direct
delivery to the bloodstream means that dosages can be less potent with the
same affect.
According to the World Health Organization, almost 350 million people
worldwide were affected by depression in 2016. Common antidepressant drugs
help maintain the balance of various hormones and chemicals in the brain which
assists in the treatment of depression.
The Center for Disease Control and Prevention (CDC), reported that the
percentage of people above the age of 12 years using antidepressants in the
U.S. rose 12.7% in 2011-2014. According to MedGadget, the antidepressant drug
market was valued at $13.69 billion in 2018 and is expected to reach $15.88
billion by 2025. The CDC said that in the U.S., antidepressants were the most
commonly prescribed drugs in 2013 and from over 16 million long term users,
around 70% are female.
"One of the critical issues surrounding the use of psilocybin is accurate
dosing in oral delivery methods. Our breakthrough technology is a game changer
in the psychedelic space and has the potential to revolutionize the way
patients receive psychedelics as medicine and reduce over concentrations and
resulting adverse effects." stated Dr. Robert E.W. Hancock, Executive Chairman
of the Company.
About Core One Labs Inc.
Core One Labs Inc. is a research and technology company focused in life
sciences and on bringing psychedelic medicines to market through novel
delivery systems and psychedelic assisted psychotherapy. The Company has
developed a patent pending thin film oral strip (the "technology"
which dissolves instantly when placed in the mouth and delivers organic molecules in
precise quantities to the bloodstream, maintaining excellent bioavailability.
With this technology, the Company intends to further develop its technology to
focus on delivering psychedelic molecules with an initial focus on psilocybin.
Core One also holds an interest in walk-in medical clinics which maintain a
database of over 200,000 patients combined. Through research and development
in these clinics, including the integration of its intellectual property
related to psychedelic treatments and novel drug therapies, the Company
intends to work towards regulatory approval for research that advances
psychedelic-derived treatments for mental health disorders.
Core One Labs Inc.
Joel Shacker
Chief Executive Officer
FOR MORE INFORMATION, PLEASE CONTACT:
info@core1labs.com
1-866-347-5058
TOODLES
7
